A story in the March 19 issue of The Cancer Letter stated that the deadline for project proposals—from intramural and extramural investigators applying for clinical grade vector and cell therapy product manufacturing at Frederick National Laboratory—is in July 2021. According to updated information from NCI, the next deadline is June 15. jQuery(document).ready(function(){ jQuery('.people-thumb + p > span.has-red-100-color, .people-thumb + p >... […]
A phase III trial evaluating Keytruda (pembrolizumab) plus Lenvima (lenvatinib) in certain patients with advanced, metastatic or recurrent endometrial cancer following one prior platinum-based regimen in any setting met its dual primary endpoints of progression-free survival and overall survival.
The phase III IMpower010 study evaluating Tecentriq (atezolizumab) compared with best supportive care met its primary endpoint of disease-free survival at the interim analysis.
The phase II/III RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma met its primary endpoint of progression-free survival.
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
SignalChem Lifesciences, and a subsidiary of Merck, are evaluating the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer.
FDA has approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation.
Evotec SE and Takeda Pharmaceutical Company Ltd. have entered into a multi-RNA target alliance to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
McKesson has received approval from The Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.
Mayo Clinic and Thermo Fisher Scientific are working together to evaluate next-generation sequencing, mass spectrometry and immunology diagnostic tools for multiple applications, including myeloid leukemia and therapeutic drug monitoring panels to deliver access to more precise and personalized insights for patient care.
